Barinthus Biotherapeutics (BRNS) Short term Debt (2021)
Barinthus Biotherapeutics (BRNS) reported Short term Debt of $159000.0 for Q4 2021.
Barinthus Biotherapeutics (BRNS) Short term Debt (2021) Analysis & Trends
Barinthus Biotherapeutics has reported Short term Debt for 1 years, with the latest figure at $159000.0 in Q4 2021.
- For the quarter ending Q4 2021, Short term Debt changed N/A year-over-year to $159000.0; the trailing twelve-month figure through Dec 2021 stood at $159000.0 (changed N/A YoY), and the FY2021 full-year result was $159000.0, changed N/A from the prior year.
- Short term Debt for Q4 2021 stood at $159000.0.
- The five-year high for Short term Debt was $159000.0 in Q4 2021, with the low at $159000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Barinthus Biotherapeutics | 27.08 Mn | -40.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 159,000.00 |